Awarded in 2014
Home Department: Bioengineering
Faculty Advisor: Edgar Engleman (Pathology)
Research Title: Simultaneous delivery of antibody and adjuvant strengthens anti-tumor immunity
Research Description: Despite the accumulation of neoantigens in the tumor microenvironment during tumorigenesis, the immune system often fails to recognize them. Recent findings in the Engleman lab uncovered that delivery of neoantigens to activated dendritic cells using antibody-tumor immune complexes can aid in overcoming this barrier. By combining DC adjuvants with antibodies capable of binding the tumor, a robust anti-tumor response was achieved. They aim to further develop this approach using protein engineering strategies to better understand the mechanism by which anti-tumor immunity is achieved.
Shelley is an associate director at Bolt Biotherapeutics, Inc., a start-up with compelling technology from Stanford that has demonstrated complete cures in numerous cancer models.